Onco-hematologia

Recomendações do consenso de especialistas sobre o diagnóstico e o tratamento da histiocitose de células de Langerhans em adultos.

17 Mar, 2022 | 12:59h

Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults – Blood

---

Diretriz NCCN | Linfomas de células T.

15 Mar, 2022 | 13:10h

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

---

Segurança e eficácia do de-escalonamento e descontinuação de antibióticos em pacientes hematológicos de alto risco com neutropenia febril: experiência de centro único.

10 Mar, 2022 | 15:17h

Safety and Efficacy of Antibiotic De-escalation and Discontinuation in High-Risk Hematological Patients With Febrile Neutropenia: A Single-Center Experience – Open Forum Infectious Diseases

Conteúdo relacionado: Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology

 

Comentário no Twitter

OFID: In high-risk hematological patients w/ febrile neutropenia, antibiotic de-escalation and discontinuation prior to neutrophil recovery did not lead to an increase in infectious complications. https://t.co/eUer1fmoc6 #IDSAJournals @PaulSaxMD @DrJLi @FungalDoc @jobadd pic.twitter.com/HuGRYA8YW3

— IDSA (@IDSAInfo) January 5, 2022

 

---

Revisão | Cardiotoxicidade da terapia com antígeno quimérico receptor de célula T para malignidades avançadas.

9 Mar, 2022 | 13:28h

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies – European Heart Journal

---

M-A | Eficácia das vacinas contra Covid-19 em pacientes imunocomprometidos.

8 Mar, 2022 | 16:16h

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

Comunicado de imprensa: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Conteúdos relacionados: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Comentário no Twitter

NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav

— The BMJ (@bmj_latest) March 3, 2022

 

---

Diretriz | Tratamento da infecção por Clostridioides difficile em receptores de transplante de células hematopoiéticas.

3 Mar, 2022 | 15:47h

American Society for Transplantation and Cellular Therapy Series: #5 – Management of Clostridioides difficile infection in hematopoietic cell transplant recipients – Transplantation and Cellular Therapy

Ver outros artigos da série:

American Society of Transplantation and Cellular Therapy Series, 1: Enterobacterales Infection Prevention and Management after Hematopoietic Cell Transplantation

 

American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients

 

American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation

 

American Society for Transplantation and Cellular Therapy Series: #4 – Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation

---

Diretrizes clínicas SEOM para profilaxia de doenças infecciosas em pacientes oncológicos.

2 Mar, 2022 | 11:35h

SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients – Clinical and Translational Oncology

---

Revisão | Tromboembolismo venoso associado a câncer.

22 Fev, 2022 | 14:37h

Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (se o acesso a este link for pago, tente este)

Infográfico: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (se o acesso a este link for pago, tente este)

Conteúdos relacionados:

NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

---

Isatuximabe com pomalidomida e baixa dose de dexametasona vs. pomalidomida e baixa dose de dexametasona em pacientes com mieloma múltiplo refratário e recidivante (ICARIA-MM): análise do seguimento de um estudo randomizado de fase 3.

22 Fev, 2022 | 14:15h

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study – The Lancet Oncology (link para o resumo – $ para o texto completo)

---

Revisão | Resposta a doses adicionais de vacinas contra COVID-19 em pessoas imunocomprometidas.

17 Fev, 2022 | 14:43h

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review – The Lancet Global Health

 

Comentário no Twitter

A review of the 23 studies of Covid vaccination for immunocompromised people indicates the level of responders varies with conditions. Even additional doses may not provide sufficient protection for some, requiring additional measureshttps://t.co/BjaKrJUAbO @LancetGH pic.twitter.com/EYVWAX23Ig

— Eric Topol (@EricTopol) February 15, 2022

 

---